Elevation Oncology Inc
ELEV
Company Profile
Business description
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.
Contact
101 Federal Street
Suite 1900
New YorkNY02110
USAT: +1 716 371-1125
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
34
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,805.00 | 21.40 | -0.24% |
| CAC 40 | 7,723.47 | 27.20 | 0.35% |
| DAX 40 | 24,073.67 | 286.22 | 1.20% |
| Dow JONES (US) | 44,406.36 | 422.17 | -0.94% |
| FTSE 100 | 8,806.53 | 16.38 | -0.19% |
| HKSE | 24,076.63 | 188.80 | 0.79% |
| NASDAQ | 20,412.52 | 188.59 | -0.92% |
| Nikkei 225 | 39,704.10 | 116.42 | 0.29% |
| NZX 50 Index | 12,859.02 | 94.07 | 0.74% |
| S&P 500 | 6,229.98 | 49.37 | -0.79% |
| S&P/ASX 200 | 8,566.30 | 23.00 | -0.27% |
| SSE Composite Index | 3,496.50 | 23.38 | 0.67% |